CyDex Pharmaceuticals Announces Successful Completion Of Phase II Clinical Trial For Budesonide/Azelastine Combination Solution Nasal Spray

CyDex Pharmaceuticals Announces Successful Completion Of Phase II Clinical Trial For Budesonide/Azelastine Combination Solution Nasal Spray
CyDex Pharmaceuticals, Inc. announced that it has successfully completed an early proof-of-concept phase II clinical trial of its Captisol-Enabled® budesonide/azelastine nasal spray for seasonal allergic rhinitis (SAR). CyDex has an international PCT patent application pending for this combination nasal spray product.